Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A. Ascierto, James Larkin, Grant A. McArthur et al.|The Lancet Oncology|2016Cited by 1k
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L. McQuade, Michael A. Davies, Carrie R. Daniel et al.|The Lancet Oncology|2018Cited by 658
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Howard S. Höchster, Luis A. Díaz et al.|Journal of Clinical Oncology|2020Cited by 391
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Karl D. Lewis et al.|The Lancet Oncology|2018Cited by 216
Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced <i>BRAF</i>-mutated melanoma.James Larkin, Antoni Ribas, Yibing Yan et al.|Journal of Clinical Oncology|2015Cited by 48